Lunai Bioworks (NASDAQ:LNAI) Lowered to “Sell” Rating by Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lunai Bioworks in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Lunai Bioworks Trading Down 1.5%

LNAI stock opened at $0.97 on Friday. Lunai Bioworks has a 1 year low of $0.81 and a 1 year high of $14.00. The stock has a market cap of $22.75 million, a P/E ratio of -13.87 and a beta of 0.37. The business has a fifty day moving average price of $1.10.

Lunai Bioworks (NASDAQ:LNAI) last posted its earnings results on Friday, November 14th. The company reported $0.13 earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks at the end of the most recent quarter. 71.41% of the stock is currently owned by institutional investors.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.